Osteoarthritis Drug Development: ‘Clinically Meaningful Endpoints’ Remain Elusive

 
• By Brenda Sandburg
osteoarthritis
There are many obstacles to developing disease-modifying osteoarthritis drugs. • Source: Alamy

More from Clinical Trials

More from R&D